ClinicalTrials.gg
Active, not recruitingNCT04591392ASCENT ASDUpdated May 7, 2025

Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

An interventional study of reSept ASD Occluder in Heart Septal Defect, Heart Septal Defects, Atrial and Heart Defects, Congenital, sponsored by atHeart Medical. Active, not recruiting at 32 sites in 4 countries. Open to participants aged Up to 84 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Primary conditionHeart Septal Defects, AtrialRegistry: Heart Septal DefectsReclassifiedWhy we changed it
Registry
Heart Septal Defects — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Septal Defects, Atrial
Why
  1. The study's listed conditions name Heart Septal Defects, Atrial, a narrower term within Heart Septal Defects.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by atHeart Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
Up to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Heart Septal Defects, Atrial with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Heart Septal Defects, Atrial · United States.

Planned enrollment
5th of 16
250 · median 155
Started
2021
with 1 other
No phase
7 of 24
none open now
Registered
19th of 24
by date
Lead sponsor
1 of 24
atHeart Medical

Among the 24 studies in Heart Septal Defects, Atrial with a site in United States, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 with no phase, and was the 19th registered.

Heart Septal Defects, Atrial

84 studies on the registry are indexed under Heart Septal Defects, Atrial; 21 are open to participants now.

Browse Heart Septal Defects, Atrial studies →

Open to participants now

3 of the 24 studies in Heart Septal Defects, Atrial with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Heart Septal Defects, Atrial studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: Up to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Heart Septal Defects, Atrial with a site in United States, or all of them as a file.
02

Study summary

Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect

Read the detailed description

Prospective, three-stage, single arm, multi-site, clinical investigation evaluating the safety and efficacy of the reSept ASD Occluder in treating clinically significant secundum ASD. Outcomes/endpoints of the clinical investigation will be compared with established performance goals for FDA approved transcatheter secundum ASD occluders.

03

Conditions studied

  • Heart Septal Defect
  • Heart Septal Defects, Atrial
  • Heart Defects, Congenital
  • Cardiovascular Abnormalities
  • Cardiovascular Diseases
  • Heart Diseases
  • Congenital Abnormalities
04

In context

Heart Septal Defects, Atrial Reclassified

84 studies on the registry are indexed under Heart Septal Defects, Atrial; 21 are open to participants now.

This study's planned enrollment of 250 is above the median of 100 across 50 interventional studies indexed under Heart Septal Defects, Atrial.

Browse Heart Septal Defects, Atrial studies →

Lead sponsor

atHeart Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Heart Septal Defects, Atrial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Septal Defects. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Up to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All responses must be Yes to be eligible:

  1. Age \< 85 years.
  2. Body weight ≥ 15 kg / 33 lb.
  3. Males and Females.
  4. , isolated secundum ASD associated with a L-R shunt and signs of RV volume overload that, based upon the expertise of attending physicians requires treatment.
  5. ASD of size 5 to 19 mm on screening diagnostic echocardiogram.
  6. Isolated secundum ASD of size 8 to 22 mm on stop flow balloon diameter, based upon echocardiographic and fluoroscopic evidence obtained at procedure.
  7. Able to take required medications: ASA (Aspirin), low dose (75-100 mg/day), 24 hours prior to and for 6 months following the procedure; Heparin intra-procedurally.
  8. Adequate septal rim to support the device. The rim is considered inadequate if it measures less than 5mm in more than two views of a critical structure
  9. Adequate defect margin to safely accommodate the selected size implant without interfering with adjacent cardiac structures (e.g., aorta, AV valves, ostia of the pulmonary veins, coronary sinus, or other critical structures), based on the IFU sizing guidance.
  10. Capable of giving , or, for minors, consent of the parent or legal guardian, and willing to comply with the clinical investigation requirements.

Exclusion criteria

Exclusion Criteria:

All responses must be No to be eligible:

  1. Pregnancy. Females with are required to be tested for pregnancy prior to treatment, in accordance with the local institution's policy. For minor females, a pregnancy test will be done in accordance with the local institution's policy.
  2. Any significant valve dysfunction that contraindicates ASD closure, or increased pulmonary vascular resistance/severe pulmonary hypertension.
  3. Acquired pathological or congenital abnormalities of the cardiovascular system (other than isolated secundum ASD; e.g. congenital malformations, calcification, myocardial infarction, intracardiac thrombi, dilated cardiomyopathy, untreated coronary disease or CAD treated with a stent in the prior 12 months) being , that would interfere with the conduct of the clinical investigation.
  4. Subjects having undergone left sided structural heart interventions performed via transseptal access (e.g. Mitraclip, LAAO, percutaneous mitral valve replacement).
  5. Evidence of thrombus in the left atrium, left atrial appendage, other cardiac chamber, or the inferior vena cava.
  6. Sepsis or any other infection that was not successfully treated at least 30 days prior to device placement.
  7. Active endocarditis or other infection(s) producing bacteremia.
  8. History of atrial tachycardia, atrial fibrillation or flutter, AV block, or ventricular arrhythmia requiring antiarrhythmic medication, pacemaker or AICD.
  9. Vasculature is of inadequate size to accommodate all procedural instrumentation.
  10. Known allergy to device components or medications, or other to clinical investigation medications (acetylsalicylic acid, heparin), including a documented history of bleeding, clotting or coagulation disorders, untreated ulcer or any other contraindications to acetylsalicylic acid or antiplatelet therapy.
  11. Known hypercoagulable state.
  12. Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation as well as any severe concurrent illness that would limit (e.g. ).
  13. Currently an active subject in an investigational drug or device study that could confound the results of this study.
  14. Patients who, in the opinion of the investigator, are inappropriate for inclusion into this clinical investigation or will not comply with requirements of the clinical investigation.
  15. Are known to abuse drugs or alcohol.
  16. Patients with the diagnosis of Patent Foramen Ovale (PFO).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Device

    ASD closure with the reSept ASD Occluder

    Device: reSept ASD Occluder

Interventions

  • DevicereSept ASD Occluder

    Transcatheter closure of secundum ASD using a permanent implant

07

What researchers measure

Primary outcomes

  1. Number of Subjects with 12-Month Composite Clinical Success

    1. Clinically effective ASD closure, defined as no residual ASD or clinically insignificant residual ASD as determined by core laboratory review; and 2. No re-intervention to treat the defect; and 3. No device or procedure related serious adverse event.

    Time frame: 12 months

  2. Number of Subjects with CEC adjudicated Device- or Procedure-related SAEs

    Incidence of subjects experiencing one or more serious device- or procedure related adverse events through the 12 month follow up visit, as adjudicated by the Clinical Events Committee (CEC)

    Time frame: 12 months

Secondary outcomes

  1. ASD Closure Success among Technical Success Subjects

    Assessment of device performance will include closure success, among subjects that were technical successes (i.e. successful placement and release of the reSept ASD Occluder at the ASD), defined as no residual ASD or clinically insignificant residual ASD determined by echocardiography. Assessment of closure success at each follow up through the 12-month follow up will be assessed by TTE.

    Time frame: 1 month, 6 months and 12 months

  2. Number of Subjects with Device- or Procedure-related AEs

    Incidence of subjects experiencing one or more non serious device- or procedure-related adverse events through the 12-month follow up visit.

    Time frame: 12 months

08

Study locations

32 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Mar 2027, 72 months after the start.

Of 19 interventional studies with no phase under Heart Septal Defects, Atrial, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 56. This study's planned 72 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Oct 19, 2020
StartActual
Mar 12, 2021
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2032
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04591392
Lead sponsor
atHeart Medical
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Mar 12, 2021
Primary completion
Mar 2027 (estimated)
Completion
Mar 2032 (estimated)
Last update
May 7, 2025

Study contacts

Thomas Forbes, MD
principal investigator · Joe DiMaggio Children&#39;s Hospital/Memorial Healthcare
Saibal Kar, MD
principal investigator · Los Robles Regional Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion